Skip to main content
. 2014 Jul 21;35(8):994–1004. doi: 10.1038/aps.2014.52

Figure 3.

Figure 3

MG132 modulates LDLR mRNA and protein levels through a PKC-dependent pathway. Western blot analysis of LDLR expression in HepG2 cells incubated with MG132 (0.3 μmol/L) under cholesterol addition (A, +cho, 2 mg/L 25-OH cholesterol and 10 mg/L cholesterol) or cholesterol depletion (B, -cho, 10 μmol/L pravastatin and 100 μmol/L mevalonlactone) conditions for the indicated times, (dep-, control of cholesterol depletion group; cho-, control of cholesterol addition group; great increase of LDLR expression in the dep group and decrease in the cho group indicating increased or decreased SREBP-2 activity). Western blot analysis of (C) mature SREBP-2 and (D) phosphorylated ERK (Pra-, pravastatin 5 μmol/L; Ber-, berberine 15 μg/L as positive controls, respectively). (E) LDLR mRNA was measured via real-time PCR, and the decay curves were plotted versus the time (MG132 0.3 μmol/L, 6 h). (F) Real-time PCR analysis of LDLR transcription in HepG2 cells incubated with GF 109203X (10 μmol/L), Gö 6983 (10 μmol/L) and staurosporine (400 nmol/L) in the presence or absence of MG132 0.3 μmol/L for 6 h, respectively. All of the values are presented as the mean±SEM of three or more independent experiments. bP<0.05, cP<0.01 vs the control groups.